PAM Inhibitor Doubles Time to Progression in Advanced Breast Cancer Subset

(MedPage Today) -- CHICAGO--A second-line triplet regimen involving the novel intravenous drug gedatolisib significantly reduced the risk of progression or death in PIK3CA-mutant hormone receptor (HR)-positive breast cancer, a phase III study...